?-3 fatty acids contribute to the asthma-protective effect of unprocessed cow's milk - 03/06/16
, Petra Ina Pfefferle, PhD, DrPH b, c, ∗the
PASTURE study group‡
Abstract |
Background |
Living on a farm has repeatedly been shown to protect children from asthma and allergies. A major factor involved in this effect is consumption of unprocessed cow's milk obtained directly from a farm. However, this phenomenon has never been shown in a longitudinal design, and the responsible milk components are still unknown.
Objectives |
We sought to assess the asthma-protective effect of unprocessed cow's milk consumption in a birth cohort and to determine whether the differences in the fatty acid (FA) composition of unprocessed farm milk and industrially processed milk contributed to this effect.
Methods |
The Protection Against Allergy—Study in Rural Environments (PASTURE) study followed 1133 children living in rural areas in 5 European countries from birth to age 6 years. In 934 children milk consumption was assessed by using yearly questionnaires, and samples of the “usually” consumed milk and serum samples of the children were collected at age 4 years. Doctor-diagnosed asthma was parent reported at age 6 years. In a nested case-control study of 35 asthmatic and 49 nonasthmatic children, 42 FAs were quantified in milk samples.
Results |
The risk of asthma at 6 years of age was reduced by previous consumption of unprocessed farm milk compared with shop milk (adjusted odds ratio for consumption at 4 years, 0.26; 95% CI, 0.10-0.67). Part of the effect was explained by the higher fat content of farm milk, particularly the higher levels of ω-3 polyunsaturated FAs (adjusted odds ratio, 0.29; 95% CI, 0.11-0.81).
Conclusion |
Continuous farm milk consumption in childhood protects against asthma at school age partially by means of higher intake of ω-3 polyunsaturated FAs, which are precursors of anti-inflammatory mediators.
Le texte complet de cet article est disponible en PDF.Key words : Allergy protection, farm milk effect, ω-3 fatty acid, asthma
Abbreviations used : aOR, BDR, FA, hsCRP, OR, PASTURE, PUFA
Plan
| P.I.P. and C.B. were supported by the European Commission (research grants QLK4-CT-2001-00250) and the Von Behring-Röntgen-Foundation vBRS (grant no. 56-0035). M.J.E. was supported by the European Commission FOOD-CT-2006-31708, and KBBE-2007-2-2-06 and the European Research Council (grant no. 250268). Y.S. was supported by the German Center for Lung Research (DZL) Disease Area, AA 1.3. |
|
| Disclosure of potential conflict of interest: T. Brick and M. J. Ege have received grants from the German Federal Ministry of Research (BMBF), the German Research Foundation (DFG), the European Commission, the European Research Council, and FrieslandCampina. J. Pekkanen has received grants from the European Union, the Academy of Finland, the Juho Vainio Foundation, the Päivikki and Sakari Sohlberg Foundation, and the Finnish Cultural Foundation. J. Genuneit has received a grant from the European Commission (FOOD-CT-2006-31708 and KBBE-2007-2-2-06). J.-C. Dalphin has received a grant from Novartis Pharma; has received personal fees from Novartis Pharma, Chiesi, Intermune, GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim; and has received nonfinancial support from Novartis, GlaxoSmithKline, AstraZeneca, Intermune, Chiesi, Boehringer Ingelheim, and Stallergenes. R. Lauener has received grants from the Kühne Foundation and the European Union; serves on advisory boards for Nestlé, Novartis, Meda, Menarini, MSD, and Allergopharma; and has received payment for lectures from Vifor. O. Vaarala is an employee of AstraZeneca R&D. E. von Mutius has received grants from the German Federal Ministry of Education and Research (BMBF), the European Commission, the European Research Council, the German Research Foundation (DFG), and FrieslandCampina; is an Associate Editor for the Journal of Allergy and Clinical Immunology; is on the Editorial Board of the New England Journal of Medicine; and has consultant arrangements with GlaxoSmithKline, Novartis, Astellas, Pharma Europe, and Vifor Pharma. |
|
| Members of the PASTURE Study Group: A. Karvonen and P. Tiittanen have received grants from the Academy of Finland (grant 139021), Juho Vainio Foundation, Kuopio University Hospital (VTR), the Farmers' Social Insurance Institution (Mela), and the Finnish Cultural Foundation. M.-L. Dalphin has received payment for lectures from Merck Sharp & Dohme and has received travel support from Stallergenes. B. Schaub has received grants from the German Research Foundation (DFG), the German Federal Ministry of Education and Research (BMBF), the European Union, and LMU. M. Depner and S. Illi have received grants from the European Research Council. M. Kabesch has received grants from the European Union, the German Ministry of Education and Research, and the German Research Foundation and has received payment for lectures from the European Respiratory Society, the European Academy of Allergy and Clinical Immunology, the American Thoracic Society, Novartis, GlaxoSmithKline, and Bencard. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 137 - N° 6
P. 1699 - juin 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
